Chloroprocaine 1% Versus Ropivacaine 0,75% During Cesarean Section
Intrathecal Use of Chloroprocaine 1% and Ropivacaine 0,75% During Elective Cesarean Section. A Comparative Study
Aretaieion University Hospital
60 participants
Jan 10, 2024
INTERVENTIONAL
Conditions
Summary
This will be a prospective randomized study, aiming at comparing an intrathecal fixed dose of chloroprocaine 1% versus an intrathecal fixed dose of ropivacaine 0.75% in elective cesarean sections
Eligibility
Inclusion Criteria3
- adult parturients, American Society of Anesthesiologists (ASA) I-II,
- singleton gestation>37 weeks
- elective cesarean section
Exclusion Criteria16
- American Society of Anesthesiologists (ASA) > III
- age < 18 years
- singleton gestation <37 weeks
- Body Mass Index (BMI) >40 kg/m2
- Body weight <50 kg
- Body weight>100 kg
- height<150 cm
- height>180 cm
- multiple gestation
- emergency delivery
- fetal abnormality
- fetal distress
- pregnancy-induced pathology such as preeclampsia, eclampsia, premature labor, placental abnormalities
- pregnancy- induced diseases such as hepatic failure, pseudocholinesterase deficiency, neuromuscular diseases
- lack of informed consent
- contraindication for regional anesthesia such as thrombocytopenia, coagulation abnormalities, allergy to local anesthetics
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
• in parturients allocated to the chloroprocaine group, a fixed dose of chloroprocaine 1% will be administered intrathecally
• in parturients allocated to the ropivacaine group, a fixed dose of ropivacaine 0.75% will be administered intrathecally
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06376058